1 / 6

ICORD 2009: Inching towards Integration--- the NIH and FDA seek IOM Input on a National Rare Disease Policy

ICORD 2009: Inching towards Integration--- the NIH and FDA seek IOM Input on a National Rare Disease Policy. Timothy Cote, MD MPH Director, Office of Orphan Products Development, Food and Drug Administration, Rockville, MD, USA Monday, Feb 23, 2009. Research Impulse Creative Peer-governance

ostinmannual
Download Presentation

ICORD 2009: Inching towards Integration--- the NIH and FDA seek IOM Input on a National Rare Disease Policy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ICORD 2009:Inching towards Integration---the NIH and FDA seek IOM Input on a National Rare Disease Policy Timothy Cote, MD MPH Director, Office of Orphan Products Development, Food and Drug Administration, Rockville, MD, USA Monday, Feb 23, 2009

  2. Research Impulse Creative Peer-governance Output: transformative ideas Require patients for data generation Regulatory Impulse Standardized Statutory governance Output: transformative actions Utilize data to make best decisions in service to patient Research and RegulationSeparate yet Symbiotic

  3. Problems • Funded research data often insufficient/inadequate for regulatory action. GMP, GCP, GLP are often ignored. • Rare disease clinical trails are unconventional: smaller size, alternative methods, unique situations. Regulatory bodies strength in standardization can hamper advancement.

  4. IOM: Highest Hopes Deliver an integrated vision of rare disease research and rare disease drug regulation.

  5. Other FDA hopes from the IOM • Analysis of existing FDA data to optimize drug development. • Determinants of maturation from designation to marketing approval • Best way to find/use abandoned orphans of promise. • Means of advancing drugs for neglected tropical diseases.

  6. Summary: the IOM Processand the Future • Big thinking • Many inputs • High hopes

More Related